ITRM,Iterum Therapeutics plc | Healthcare

Healthcare

ITRM

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

Iterum Therapeutics plcITRM

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.

It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Latest News >

Dutch Senate approves law to permanently close Groningen gas field

Apr 16, 2024

AMSTERDAM, April 16 (Reuters) - The Dutch Senate on Tuesday approved a law to permanently close the Groningen gas field in the north of the Netherlands, following the government's promise that production will never be resumed to limit seismic risks in the region. Normal gas production at Groningen in the north of the Netherlands ended last October after years of...

Hancock Whitney Q1 Earnings, Revenue Decline

Apr 16, 2024

04:22 PM EDT, 04/16/2024 (MT Newswires) -- Hancock Whitney ( HWC ) reported Q1 earnings Tuesday of $1.24 per diluted share, down from $1.45 a year earlier. Analysts polled by Capital IQ expected $1.17. Revenue in the quarter ended March 31, expressed as the sum of net interest income and noninterest income, was $354 million, down from $365.3 million a...

Accenture Insider Sold Shares Worth $474,213, According to a Recent SEC Filing

Apr 16, 2024

04:23 PM EDT, 04/16/2024 (MT Newswires) -- Manish Sharma, CEO, North America, on April 12, 2024, sold 1,501 shares in Accenture ( ACN ) for $474,213. Following the Form 4 filing with the SEC, Sharma has control over a total of 3,122 shares of the company, with 3,122 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1467373/000146737324000130/xslF345X03/wk-form4_1713298245.xml ...

Accenture Insider Sold Shares Worth $1,200,855, According to a Recent SEC Filing

Apr 16, 2024

04:22 PM EDT, 04/16/2024 (MT Newswires) -- Julie Spellman Sweet, Director, Chair and CEO, on April 12, 2024, sold 3,801 shares in Accenture ( ACN ) for $1,200,855. Following the Form 4 filing with the SEC, Sweet has control over a total of 15,178 shares of the company, with 15,178 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1467373/000146737324000131/xslF345X03/wk-form4_1713298263.xml ...